Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study
Beam Therapeutics announced Tuesday that its base-edited sickle cell therapy succeeded in a clinical trial, meaning a third one-time therapy for the disease may soon enter the market. In Beam’s Phase 1/2 trial, known as ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Beam’s base editing therapy for sickle cell hits goal in pivotal trial biopharmadive.com
